04K Stock Overview Develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. More details
Rewards Risk Analysis No risks detected for 04K from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Knight Therapeutics Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Knight Therapeutics Historical stock prices Current Share Price CA$3.86 52 Week High CA$4.12 52 Week Low CA$3.40 Beta 0.48 1 Month Change 6.04% 3 Month Change 12.87% 1 Year Change -0.52% 3 Year Change 3.76% 5 Year Change -25.77% Change since IPO 0.92%
Recent News & Updates
Knight Therapeutics Inc. Announces Filing of New Drug Submission for Qelbree® (Viloxazine) in Canada Dec 17
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Mexico Dec 13
Knight Therapeutics Inc. Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder Nov 15
President recently bought €69k worth of stock Nov 12
Third quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.09 in 3Q 2023) Nov 09
Knight Therapeutics Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 31 See more updates
Knight Therapeutics Inc. Announces Filing of New Drug Submission for Qelbree® (Viloxazine) in Canada Dec 17
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Mexico Dec 13
Knight Therapeutics Inc. Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder Nov 15
President recently bought €69k worth of stock Nov 12
Third quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.09 in 3Q 2023) Nov 09
Knight Therapeutics Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 31
Second quarter 2024 earnings released: CA$0.019 loss per share (vs CA$0.017 profit in 2Q 2023) Aug 09
Knight Therapeutics Inc. Revises Earnings Guidance for the Year 2024 Aug 09
Knight Therapeutics Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
Independent Director recently sold €100k worth of stock May 30
Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024 May 10
First quarter 2024 earnings released: CA$0.045 loss per share (vs CA$0.035 loss in 1Q 2023) May 09
Knight Therapeutics Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Full year 2023 earnings released: CA$0.16 loss per share (vs CA$0.26 loss in FY 2022) Mar 21
Knight Therapeutics Inc. to Report Q4, 2023 Results on Mar 21, 2024 Mar 15
Knight Therapeutics Inc., Annual General Meeting, May 08, 2024 Feb 24
Knight Therapeutics Inc. Announces Regulatory Submission of Fostamatinib in Brazil Feb 23
Knight Therapeutics Inc. Announces Launch of Bijuva® in Canada Feb 06
Third quarter 2023 earnings released: EPS: CA$0.09 (vs CA$0.014 in 3Q 2022) Nov 11
Knight Therapeutics Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 03
Knight Therapeutics Inc. Announces CMED Price Approval of Minjuvi (tafasitamab) in Brazil Oct 17
United Medical Ltd. Announces Regulatory Submission of Pemigatinib in Brazil Oct 11
Executive Chairman recently bought €77k worth of stock Sep 28
Knight Therapeutics Inc. Updates Earnings Guidance for the Fiscal Year 2023 Aug 11
Second quarter 2023 earnings released: EPS: CA$0.017 (vs CA$0.022 in 2Q 2022) Aug 11 Knight Therapeutics Inc. to Report Q2, 2023 Results on Aug 10, 2023 Aug 04
Insufficient new directors Jul 02
President recently bought €65k worth of stock May 26
Knight Therapeutics Inc. Updates Revenue Guidance for the Fiscal 2023 May 13
First quarter 2023 earnings released: CA$0.035 loss per share (vs CA$0.16 loss in 1Q 2022) May 12
Knight Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023 May 05
Full year 2022 earnings released: CA$0.26 loss per share (vs CA$0.13 profit in FY 2021) Mar 30
Knight Therapeutics Inc. Announces Relaunch of AKYNZEO in Canada Dec 02
Third quarter 2022 earnings released: EPS: CA$0.014 (vs CA$0.07 loss in 3Q 2021) Nov 16
Third quarter 2022 earnings released: EPS: CA$0.014 (vs CA$0.07 loss in 3Q 2021) Nov 11 Knight Therapeutics Inc. Reports Impairment of Intangible Assets for the Third Quarter Ended September 30, 2022
Knight Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 04
Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil Oct 07
Second quarter 2022 earnings released: EPS: CA$0.022 (vs CA$0.23 in 2Q 2021) Aug 12
Knight Therapeutics Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 05
Executive Chairman recently bought €100k worth of stock Jul 09
Executive Chairman recently bought €76k worth of stock Jun 18
Executive Chairman recently bought €153k worth of stock May 20
First quarter 2022 earnings released: CA$0.16 loss per share (vs CA$0.028 profit in 1Q 2021) May 13
Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2022 May 13
Knight Therapeutics Inc. to Report Q1, 2022 Results on May 12, 2022 May 06
Independent Director recently bought €65k worth of stock Apr 15
President recently bought €74k worth of stock Apr 02
Full year 2021 earnings released: EPS: CA$0.13 (vs CA$0.32 in FY 2020) Mar 29
Knight Therapeutics Inc., Annual General Meeting, May 11, 2022 Feb 26
Knight Therapeutics Inc. Announces Approval of Halaven® in Colombia Jan 07
Executive Chairman recently bought €71k worth of stock Jan 06
Knight Therapeutics Inc. Announces Approval of Lenvima® in Colombia Jan 06
President recently bought €57k worth of stock Dec 15
Executive Chairman recently bought €73k worth of stock Dec 08
Executive Chairman recently bought €66k worth of stock Nov 17
Third quarter 2021 earnings released: CA$0.07 loss per share (vs CA$0.14 profit in 3Q 2020) Nov 12
High number of new directors Nov 01
High number of new directors Oct 02
Executive Chairman recently bought €70k worth of stock Sep 22
CEO & Director recently bought €137k worth of stock Aug 20
Second quarter 2021 earnings released: EPS CA$0.23 (vs CA$0.13 in 2Q 2020) Aug 14
CEO & Director recently bought €64k worth of stock Jul 04
CEO & Director recently bought €128k worth of stock May 28
Knight Therapeutics Announces Closing of Previously Announce Acquisition and Exclusive License to Exelon® in Canada and Latin America May 27
First quarter 2021 earnings released: EPS CA$0.028 (vs CA$0.013 loss in 1Q 2020) May 15
Full year 2020 earnings released: EPS CA$0.32 (vs CA$0.10 in FY 2019) Mar 27
Knight Therapeutics Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2020 Mar 27
Knight Therapeutics Inc. to Report Q4, 2020 Results on Mar 25, 2021 Mar 19
New 90-day low: €3.26 Mar 05
Knight Therapeutics Inc., Annual General Meeting, May 13, 2021 Feb 26
New 90-day high: €3.70 Jan 21
Independent Director recently bought €68k worth of stock Jan 15
New 90-day low: €3.32 Dec 15
Founder recently bought €76k worth of stock Dec 06
New 90-day low: €3.36 Nov 16
Revenue misses expectations Nov 14
Third quarter 2020 earnings released: EPS CA$0.14 Nov 14
Knight Therapeutics Inc. to Report Q3, 2020 Results on Nov 13, 2020 Nov 07
New 90-day low: €3.48 Oct 30
Knight Therapeutics Inc. Signs New Exclusive AmBisome® Agreement with Gilead in Brazil Oct 27
New 90-day low: €3.66 Sep 30 Knight Therapeutics Inc and TherapeuticsMD, Inc. Announce Health Canada Approval of BIJUVA
New 90-day low - €3.74 Sep 15
New 90-day low - €4.14 Aug 21
First half earnings released Aug 14
Knight Therapeutics Inc. to Report Q2, 2020 Results on Aug 13, 2020 Aug 07
New 90-day low - €4.32 Jul 22 Shareholder Returns 04K DE Pharmaceuticals DE Market 7D 1.0% -3.9% -0.02% 1Y -0.5% -12.4% 15.1%
See full shareholder returns
Return vs Market: 04K underperformed the German Market which returned 15.3% over the past year.
Price Volatility Is 04K's price volatile compared to industry and market? 04K volatility 04K Average Weekly Movement 4.6% Pharmaceuticals Industry Average Movement 5.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 04K has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 04K's weekly volatility (5%) has been stable over the past year.
About the Company Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation.
Show more Knight Therapeutics Inc. Fundamentals Summary How do Knight Therapeutics's earnings and revenue compare to its market cap? 04K fundamental statistics Market cap €390.97m Earnings (TTM ) -€20.83m Revenue (TTM ) €236.36m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 04K income statement (TTM ) Revenue CA$348.64m Cost of Revenue CA$180.37m Gross Profit CA$168.27m Other Expenses CA$199.00m Earnings -CA$30.73m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.31 Gross Margin 48.26% Net Profit Margin -8.81% Debt/Equity Ratio 6.7%
How did 04K perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/07 14:39 End of Day Share Price 2025/02/07 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Knight Therapeutics Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Kideckel Beacon Securities Limited David Martin Bloom Burton & Co. Tania Armstrong-Whitworth Canaccord Genuity
Show 13 more analysts 
